Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 7:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 200 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adenovirus Infection Clear all
Recruiting Phase 1 Interventional

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

NCT03896568
View directory record Official record
Conditions
IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
Interventions
Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

NCT04706923
View directory record Official record
Conditions
Adenovirus Infections, Cytomegalovirus Infection
Interventions
BCV
Drug
Lead sponsor
SymBio Pharmaceuticals
Industry
Eligibility
2 Months and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection

NCT00109629
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 7:24 AM EDT
Terminated Phase 2 Interventional Results available

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

NCT03050814
View directory record Official record
Conditions
Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer
Interventions
Avelumab, Ad-CEA vaccine, Bevacizumab, 5-Fluorouracil (FU), Leucovorin, Oxaliplatin, Capecitabine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

NCT00472719
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP, VRC-HIVDNA044-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

NCT04453202
View directory record Official record
Conditions
Healthy
Interventions
RSV Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
San Diego, California • Coral Gables, Florida • El Dorado, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

NCT04693637
View directory record Official record
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions
Posoleucel (ALVR105)
Biological
Lead sponsor
AlloVir
Industry
Eligibility
1 Year and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 9, 2026, 7:24 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

NCT05067933
View directory record Official record
Conditions
COVID-19
Interventions
VXA-CoV2-1.1-S, Placebo Tablets
Drug · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Long Beach, California • Wichita, Kansas • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

NCT00125970
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP placebo, VRC-HIVADV014-00-VP placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 9, 2026, 7:24 AM EDT
Recruiting Phase 1 Interventional

Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals

NCT02455479
View directory record Official record
Conditions
Cocaine Dependence
Interventions
dAd5GNE Vaccine, Placebo
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 69 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

NCT06620003
View directory record Official record
Conditions
Marburg Virus Disease
Interventions
cAd3-Marburg Vaccine, Placebo
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
7
States / cities
Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Adenovirus Vaccine Pregnancy Registry

NCT01584037
View directory record Official record
Conditions
Adenovirus
Interventions
Not listed
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
17 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

NCT00709605
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional

Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT00850057
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Intranodal injection of Ad-ISF35
Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 9, 2026, 7:24 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

NCT03878121
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ad4-Env145NFL, Ad4-Env150KN, VRC-HIVRGP096-00-VP (Trimer 4571) with alum
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional

First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

NCT04053283
View directory record Official record
Conditions
Metastatic Cancer, Epithelial Tumor
Interventions
NG-641
Biological
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Santa Barbara, California • Celebration, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 9, 2026, 7:24 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis

NCT03594981
View directory record Official record
Conditions
Viral Infection
Interventions
CMV/AdV /EBV/BKV specific T cells
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

NCT03754933
View directory record Official record
Conditions
Recurrent Head and Neck Cancer
Interventions
Ad/PNP, Fludarabine Phosphate
Biological · Drug
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Stanford, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

NCT01533480
View directory record Official record
Conditions
Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Interventions
Zirgan, genteal gel
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed

NCT00003649
View directory record Official record
Conditions
Lung Cancer
Interventions
Ad5CMV-p53 gene
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
3
States / cities
Nashville, Tennessee • Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 9, 2026, 7:24 AM EDT
Terminated Phase 1 Interventional

Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma

NCT00415454
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Ad5-yCD/mutTKSR39rep-ADP
Genetic
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 9, 2026, 7:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

NCT04854746
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-GI.1.NN, Placebo Tablet
Biological
Lead sponsor
Vaxart
Industry
Eligibility
55 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Cypress, California • New Orleans, Louisiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 9, 2026, 7:24 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 9, 2026, 7:24 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

NCT02143804
View directory record Official record
Conditions
Bladder Cancer, High Grade, Non Muscle Invasive
Interventions
oncolytic adenovirus expressing GMCSF
Biological
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 9, 2026, 7:24 AM EDT